

**Remarks**

Claims 1, 3-38, 41-43 and new claims 45-47 are pending in this application.

Claims 1, 3-38 and 41-43 have been amended to provide clarity for that which Applicants regard as their invention and consistency with procedural requirements within the United States Patent and Trademark Office. Claims 1, 4-31 and 32-37 have been amended for purposes of clarity regarding the phrase "including their enantiomers" and included the phrase "or a pharmaceutically acceptable salt thereof." Support for these amendments is found at least in cancelled Claims 2 and at page 9, lines 28-32 and page 10, lines 4-30 of the disclosure. The disclosure makes it clear that individual isomers and combinations of isomers are within the scope of the claims as amended.

Claims 3 and 32 have been amended to provide a proper Markush group format. Claim dependencies have been amended on Claims 38 and 41-43. New Claims 45-47 have been added and are supported at least by page 8, lines 1-3 of the disclosure. Applicants contend no new matter has been added by any of the amendments.

Applicants request favorable consideration of this application.

Respectfully submitted,



John C. Demeter  
Attorney for Applicant(s)  
Registration No. 30,167  
Phone: 317-276-3785

Eli Lilly and Company  
Patent Division  
P.O. Box 6288  
Indianapolis, Indiana 46206-6288

August 25, 2005